Next-generation sequencing or whole exome sequencing of 29 of the 32 cases of AML enrolled in the phase II venetoclax monotherapy study suggested that SRSF2/ZRSR2 and IDH1/2 mutations may predict sensitivity to venetoclax therapy in AML[138,159]. The gene discussed is ZRSR2; the disease is acute myeloid leukemia.